NO993779D0 - Fremgangsmåte for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-lösningsmiddel - Google Patents

Fremgangsmåte for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-lösningsmiddel

Info

Publication number
NO993779D0
NO993779D0 NO993779A NO993779A NO993779D0 NO 993779 D0 NO993779 D0 NO 993779D0 NO 993779 A NO993779 A NO 993779A NO 993779 A NO993779 A NO 993779A NO 993779 D0 NO993779 D0 NO 993779D0
Authority
NO
Norway
Prior art keywords
solvent
crystallizing
reverse transcriptase
transcriptase inhibitor
crystallising
Prior art date
Application number
NO993779A
Other languages
English (en)
Other versions
NO993779L (no
NO320128B1 (no
Inventor
William Clarke
Louis S Crocker
Ii Joseph L Kukura
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO993779(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9706046.1A external-priority patent/GB9706046D0/en
Priority claimed from GBGB9709348.8A external-priority patent/GB9709348D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO993779D0 publication Critical patent/NO993779D0/no
Publication of NO993779L publication Critical patent/NO993779L/no
Publication of NO320128B1 publication Critical patent/NO320128B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19993779A 1997-02-05 1999-08-04 Fremgangsmate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-losningsmiddel NO320128B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3738597P 1997-02-05 1997-02-05
GBGB9706046.1A GB9706046D0 (en) 1997-03-24 1997-03-24 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US4280797P 1997-04-08 1997-04-08
GBGB9709348.8A GB9709348D0 (en) 1997-05-07 1997-05-07 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
PCT/US1998/001999 WO1998033782A1 (en) 1997-02-05 1998-02-02 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent

Publications (3)

Publication Number Publication Date
NO993779D0 true NO993779D0 (no) 1999-08-04
NO993779L NO993779L (no) 1999-10-05
NO320128B1 NO320128B1 (no) 2005-10-31

Family

ID=27451618

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19993779A NO320128B1 (no) 1997-02-05 1999-08-04 Fremgangsmate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-losningsmiddel

Country Status (18)

Country Link
EP (1) EP0975609B1 (no)
JP (6) JP3418626B2 (no)
KR (1) KR100573192B1 (no)
CN (2) CN1073991C (no)
AT (1) ATE486065T1 (no)
AU (1) AU738545C (no)
CA (1) CA2279198C (no)
CZ (2) CZ304186B6 (no)
DE (1) DE69841972D1 (no)
EA (1) EA001805B1 (no)
EE (1) EE03827B1 (no)
HU (1) HU229087B1 (no)
IL (1) IL130715A (no)
NO (1) NO320128B1 (no)
NZ (1) NZ336510A (no)
PL (1) PL197740B1 (no)
SK (1) SK284935B6 (no)
WO (1) WO1998033782A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486065T1 (de) * 1997-02-05 2010-11-15 Merck Sharp & Dohme Verfahren zur kristallisation eines reverstranskriptase-inhibitors, bei welchem ein anti-lösungsmittel benutzt wird
AR011731A1 (es) * 1997-05-16 2000-08-30 Merck & Co Inc Un proceso de reaccion de adicion enantioselectiva eficiente utilizando un reactivo de organozinc.
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
US20060235008A1 (en) * 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
WO2008108630A1 (en) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Polymorphic forms of efavirenz
WO2009087679A2 (en) * 2007-12-24 2009-07-16 Matrix Laboratories Limited Process for preparing polymorphic forms of (s)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one
EP2367804B1 (en) 2008-12-22 2013-11-06 Hetero Research Foundation Process for preparing efavirenz polymorph
DE102009041443A1 (de) 2009-09-16 2011-03-31 Archimica Gmbh Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
CN105037175B (zh) * 2014-07-18 2017-02-22 盐城迪赛诺制药有限公司 一种用于提高依非韦伦中间体光学纯度的方法
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913999PA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN114195761B (zh) * 2021-12-23 2023-04-14 浙江普洛家园药业有限公司 一种高纯度西他沙星3/2水合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5663169A (en) * 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
ATE486065T1 (de) * 1997-02-05 2010-11-15 Merck Sharp & Dohme Verfahren zur kristallisation eines reverstranskriptase-inhibitors, bei welchem ein anti-lösungsmittel benutzt wird
EA199900911A1 (ru) * 1997-04-07 2000-04-24 Дюпон Фармасьютикалз Компани Асимметрический синтез бензоксазинонов через новые промежуточные соединения

Also Published As

Publication number Publication date
CN1191242C (zh) 2005-03-02
CA2279198C (en) 2009-04-14
JP2017061575A (ja) 2017-03-30
EP0975609B1 (en) 2010-10-27
EA001805B1 (ru) 2001-08-27
DE69841972D1 (de) 2010-12-09
PL197740B1 (pl) 2008-04-30
SK105599A3 (en) 2000-05-16
HUP0001313A3 (en) 2002-12-28
NO993779L (no) 1999-10-05
JP2003040874A (ja) 2003-02-13
CZ297535B6 (cs) 2007-01-03
CZ304186B6 (cs) 2013-12-11
WO1998033782A1 (en) 1998-08-06
KR20000070735A (ko) 2000-11-25
SK284935B6 (sk) 2006-02-02
JP2011006472A (ja) 2011-01-13
EA199900720A1 (ru) 2000-04-24
AU738545B2 (en) 2001-09-20
PL334478A1 (en) 2000-02-28
NZ336510A (en) 2001-04-27
JP2013139484A (ja) 2013-07-18
HUP0001313A2 (hu) 2000-10-28
KR100573192B1 (ko) 2006-04-24
HU229087B1 (en) 2013-07-29
IL130715A (en) 2003-07-31
ATE486065T1 (de) 2010-11-15
AU6263298A (en) 1998-08-25
CN1073991C (zh) 2001-10-31
CN1385425A (zh) 2002-12-18
EP0975609A1 (en) 2000-02-02
AU738545C (en) 2004-06-17
JP5295190B2 (ja) 2013-09-18
EE9900341A (et) 2000-02-15
EE03827B1 (et) 2002-08-15
IL130715A0 (en) 2000-06-01
CA2279198A1 (en) 1998-08-06
JP2015205914A (ja) 2015-11-19
CN1246113A (zh) 2000-03-01
NO320128B1 (no) 2005-10-31
CZ276599A3 (cs) 2000-02-16
EP0975609A4 (en) 2001-02-21
JP6126172B2 (ja) 2017-05-10
JP3418626B2 (ja) 2003-06-23
JP2000507972A (ja) 2000-06-27

Similar Documents

Publication Publication Date Title
NO993779L (no) Fremgangsmaate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-lösningsmiddel
TW365025B (en) Manufacturing method for gallium nitride crystal
ATE510798T1 (de) Verfahren zur herstellung eines kristallinen, zeolithischen feststoffs
GT199900100A (es) Metodo y aparato para recolectar datos de tiempo de paralizacion y equipo de fabricacion.
KR960026070A (ko) 반도체 웨이퍼 생산 방법
EP1428818A3 (en) Method for producing N-carbamate-protected beta-aminoepoxide and beta-aminoalcohol
EP1134016A3 (en) Method and apparatus for recovering volatile organic compounds from exhaust gas
DK0689579T3 (da) Fremgangsmåde til ekstraktion af sphingomyelin
CA2319788A1 (en) A method of modifying a crystalline molecular sieve material
DE60014088D1 (de) Verfahren zur herstellung von (nitroxymethyl)phenylestern von salicylsäurederivaten
WO2003016330A3 (en) Molecular linkers suitable for crystallization and structural analysis of molecules of interest, method of using same, and methods of purifying g protein-coupled receptors
DK155947C (da) I det vaesentlige rene, vandfrie eller hydratiserede salte af l-aspartyl-d-aminosyre-dipeptid-amider med aromatiske sulfonsyrer og fremgangsmaade til fremstilling deraf
DE60024821D1 (de) Verfahren zur reinigung von aldehydverunreinigungen
DK1124812T3 (da) Fremgangsmåde til epoxidering af olefiner
KR100740474B1 (ko) 기판을 처리하는 장치 및 방법
BR0204562A (pt) Método de controle para transmissão automática de veìculos motorizados
DE69901792D1 (de) Verfahren zur herstellung von 2-acetylthio-3-phenyl-propionsäure und deren salzen
NO20061582L (no) Fremgangsmate og anlegg for behandling av avlopsvann
ATE189825T1 (de) Verfahren und vorrichtung zur reinigung von polyolefin
DK1476422T3 (da) Fremgangsmåde til behandling af en organisk imidoplösning, som er bærer af en sulfonylgruppe
DK0474509T3 (da) Fremgangsmåde til oprensning af blandinger omfattende ibuprofen
DK0799177T3 (da) Fremgangsmåde til fremstilling af faste, fritfllydende, vandopløselige salte af aryloxy-C - C -alkancarboxylsyrer
DK518587A (da) Fremgangsmaade til at foelge syntesen af en lineaer kombination af aminosyrerester
JPH10263866A (ja) レーザー切断加工方法
KR950021251A (ko) 반도체 제조방법 및 그 제조장치

Legal Events

Date Code Title Description
MK1K Patent expired